Looking back at the past year, how has the pandemic and associated supply chain issues affected the development of controlled release products? John Tillotson, Pharmaceutical Technical Business Director, ABITEC Corporation: Primarily, the pandemic has challenged supply chain logistics and increased the manufacturing costs of numerous excipients including controlled-release excipients. This includes the cost of developing controlled release products. Nathan Dormer, Director of Drug Product Development, Adare Pharma Solutions: The pandemic has invariably affected every industry's supply chain and Adare Pharma Solutions has been no exception.
展开▼
